Related Experiment Videos
[Statistical significance or clinical relevance?]
Els K Vanhoutte1, Catharina G Faber, Ingemar S J Merkies
1Maastricht Universitair Medisch Centrum, afd. Neurologie, Maastricht, the Netherlands. els@van-houtte.net
Abstract:
This article evaluates the concept of 'minimal clinically important difference' (MCID) through the results of two studies. The first study was a randomised trial in patients with Parkinson's disease claiming a positive effect of treatment with rasagiline over placebo, based on statistical differences in ordinal outcome measures. However, the clinical relevance of the findings according to the concept of MCID was not taken into consideration. In the second study, MCIDs were defined by several methods in a large trial in patients with chronic inflammatory demyelinating polyneuropathy receiving intravenous immunoglobulin (IGIV) or placebo. In that study, the differences in outcomes between the intervention group and the placebo group were not only statistically significant, but also clinically relevant, in favour of the intervention group. This was demonstrated using various MCID cut-off values.
Insights
The minimal clinically important difference (MCID) is crucial for assessing treatment effectiveness. One study showed statistical significance without clinical relevance, while another demonstrated both statistical and clinical importance for IGIV in polyneuropathy.
Area of Science:
- Clinical Trials
- Neurology
- Biostatistics
Context:
- Evaluating treatment efficacy requires assessing both statistical significance and clinical relevance.
- The concept of Minimal Clinically Important Difference (MCID) provides a framework for determining clinical relevance.
- Two studies are examined to illustrate the application and importance of MCID in clinical research.
Purpose:
- To evaluate the concept of Minimal Clinically Important Difference (MCID) in clinical research.
- To assess whether statistically significant treatment effects translate into clinically meaningful improvements for patients.
- To highlight the importance of considering MCID alongside statistical significance in interpreting trial results.
Summary:
- A randomized trial in Parkinson's disease demonstrated statistical differences with rasagiline but did not consider MCID, questioning the clinical relevance.
- A separate large trial in chronic inflammatory demyelinating polyneuropathy (CIDP) defined MCIDs using multiple methods.
- This CIDP trial showed statistically significant and clinically relevant benefits of intravenous immunoglobulin (IGIV) over placebo, confirmed by various MCID thresholds.
Impact:
- Emphasizes the necessity of incorporating MCID assessments in clinical trials to ensure reported benefits are meaningful to patients.
- Suggests that statistical significance alone is insufficient for claiming treatment effectiveness.
- Provides evidence for the clinical utility of IGIV in CIDP when assessed against established MCID values.
Related Concept Videos
Statistical Significance
Significance Testing: Overview
Bioequivalence Data: Statistical Interpretation
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Statistical Hypothesis Testing
Statistical significance measures the probability that an observed result occurred by chance. If this probability, known as...
Critical Region, Critical Values and Significance Level
In hypothesis testing, a sample statistic is converted to a test statistic using z, t, or chi-square distribution. A critical region is an area under the curve in probability distributions demarcated by the critical value. When the test statistic falls in this region, it suggests that the null hypothesis must be rejected. As this region contains all those values of the test...